Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Martine P, Roudier"'
Autor:
Azra Ajkunic, Erolcan Sayar, Martine P. Roudier, Radhika A. Patel, Ilsa M. Coleman, Navonil De Sarkar, Brian Hanratty, Mohamed Adil, Jimmy Zhao, Samir Zaidi, Lawrence D. True, Jamie M. Sperger, Heather H. Cheng, Evan Y. Yu, Robert B. Montgomery, Jessica E. Hawley, Gavin Ha, Thomas Persse, Patricia Galipeau, John K. Lee, Stephanie A. Harmon, Eva Corey, Joshua M. Lang, Charles L. Sawyers, Colm Morrissey, Michael T. Schweizer, Roman Gulati, Peter S. Nelson, Michael C. Haffner
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-9 (2024)
Abstract Therapeutic approaches targeting proteins on the surface of cancer cells have emerged as an important strategy for precision oncology. To capitalize on the potential impact of drugs targeting surface proteins, detailed knowledge about the ex
Externí odkaz:
https://doaj.org/article/cdd085eaf0e84556a25f843f3b873e3c
Autor:
Vipul Bhatia, Nikhil V. Kamat, Tiffany E. Pariva, Li-Ting Wu, Annabelle Tsao, Koichi Sasaki, Huiyun Sun, Gerardo Javier, Sam Nutt, Ilsa Coleman, Lauren Hitchcock, Ailin Zhang, Dmytro Rudoy, Roman Gulati, Radhika A. Patel, Martine P. Roudier, Lawrence D. True, Shivani Srivastava, Colm M. Morrissey, Michael C. Haffner, Peter S. Nelson, Saul J. Priceman, Jun Ishihara, John K. Lee
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-23 (2023)
Abstract Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a cell surface antigen for therapeutic targeting in prostate cancer. Here, we report broad expression of STEAP1 relative to prostate-specific membrane antigen (PSMA) in letha
Externí odkaz:
https://doaj.org/article/ba31d0647dda46c882a031a7d7f3aece
Autor:
Deyong Jia, Zhicheng Zhou, Oh-Joon Kwon, Li Zhang, Xing Wei, Yiqun Zhang, Mingyang Yi, Martine P. Roudier, Mary C. Regier, Ruth Dumpit, Peter S. Nelson, Mark Headley, Lawrence True, Daniel W. Lin, Colm Morrissey, Chad J. Creighton, Li Xin
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-18 (2022)
Forkhead transcription factor FoxF2 plays a crucial role in the development of organs derived from primitive gut. Here the authors show that reduction of Foxf2 expression in stromal cells is associated with high grade prostate cancer and that increas
Externí odkaz:
https://doaj.org/article/6ef1b8477dc94cb884e5bb6309eb3423
Autor:
Erolcan Sayar, Radhika A. Patel, Ilsa M. Coleman, Martine P. Roudier, Ailin Zhang, Pallabi Mustafi, Jin-Yih Low, Brian Hanratty, Lisa S. Ang, Vipul Bhatia, Mohamed Adil, Hasim Bakbak, David A. Quigley, Michael T. Schweizer, Jessica E. Hawley, Lori Kollath, Lawrence D. True, Felix Y. Feng, Neil H. Bander, Eva Corey, John K. Lee, Colm Morrissey, Roman Gulati, Peter S. Nelson, Michael C. Haffner
Publikováno v:
JCI Insight, Vol 8, Iss 7 (2023)
Prostate-specific membrane antigen (PSMA) is an important cell surface target in prostate cancer. There are limited data on the heterogeneity of PSMA tissue expression in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, the mecha
Externí odkaz:
https://doaj.org/article/bf1e39c95aad42bb924c7ccfb3af7d25
Autor:
Johanne I. Weberpals, Trevor J. Pugh, Paola Marco‐Casanova, Glenwood D. Goss, Natalie Andrews Wright, Prisni Rath, Jonathon Torchia, Alexander Fortuna, Gemma N. Jones, Martine P. Roudier, Laurence Bernard, Bryan Lo, Dax Torti, Alberto Leon, Kayla Marsh, Darren Hodgson, Marc Duciaume, William J. Howat, Natalia Lukashchuk, Stanley E. Lazic, Doreen Whelan, Harmanjatinder S. Sekhon
Publikováno v:
Cancer Medicine, Vol 10, Iss 9, Pp 3045-3058 (2021)
Abstract Background In high grade serous ovarian cancer (HGSOC), there is a spectrum of sensitivity to first line platinum‐based chemotherapy. This study molecularly characterizes HGSOC patients from two distinct groups of chemotherapy responders (
Externí odkaz:
https://doaj.org/article/8826b110dfd043bcab07785ab9fa87ae
Autor:
Dimitrios Makrakis, Jonathan L. Wright, Martine P. Roudier, Jose Garcia, Funda Vakar-Lopez, Michael P. Porter, Yan Wang, Atreya Dash, Daniel Lin, George Schade, Brian Winters, Xiotun Zhang, Peter Nelson, Elahe Mostaghel, Heather H. Cheng, Michael Schweizer, Sarah K. Holt, John L. Gore, Evan Y. Yu, Hung Ming Lam, Bruce Montgomery
Publikováno v:
Clinical Genitourinary Cancer. 21:265-272
Autor:
Fady Ghali, Funda Vakar-Lopez, Martine P. Roudier, Jose Garcia, Sonali Arora, Heather H. Cheng, Michael T. Schweizer, Michael Haffner, John K. Lee, Evan Y. Yu, Petros Grivas, Bruce Montgomery, Andrew C. Hsieh, Jonathan L. Wright, Hung-Ming Lam
Publikováno v:
Clinical Genitourinary Cancer.
Autor:
Ilsa M. Coleman, Navonil DeSarkar, Colm Morrissey, Li Xin, Martine P. Roudier, Erolcan Sayar, Dapei Li, Eva Corey, Michael C. Haffner, Peter S. Nelson
Publikováno v:
Clinical Cancer Research. 28:3127-3140
Purpose: To determine whether metastatic castration–resistant prostate cancers (mCRPC) partition into molecular phenotypes corresponding to intrinsic differentiation states and ascertain whether these subtypes exhibit specific druggable features an
Autor:
Radhika A. Patel, Ilsa Coleman, Martine P. Roudier, Eric Q. Konnick, Brian Hanratty, Ruth Dumpit, Jared M. Lucas, Lisa S. Ang, Jin-Yih Low, Maria S. Tretiakova, Gavin Ha, John K. Lee, Lawrence D. True, Angelo M. De Marzo, Peter S. Nelson, Colm Morrissey, Colin C. Pritchard, Michael C. Haffner
Publikováno v:
Cancer Res Commun
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase with genomic and expression changes in many solid tumors. ALK inhibition is the first-line therapy for lung cancers with ALK alterations, and an effective therapy in other tumor types, but has not
Autor:
Michael C. Haffner, Colin C. Pritchard, Colm Morrissey, Peter S. Nelson, Angelo M. De Marzo, Lawrence D. True, John K. Lee, Gavin Ha, Maria S. Tretiakova, Jin-Yih Low, Lisa S. Ang, Jared M. Lucas, Ruth Dumpit, Brian Hanratty, Eric Q. Konnick, Martine P. Roudier, Ilsa Coleman, Radhika A. Patel
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase with genomic and expression changes in many solid tumors. ALK inhibition is the first-line therapy for lung cancers with ALK alterations, and an effective therapy in other tumor types, but has not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25646326e6abdc2a05ef2261ba0945d7
https://doi.org/10.1158/2767-9764.c.6550595.v1
https://doi.org/10.1158/2767-9764.c.6550595.v1